Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
about
Febuxostat for treating chronic goutFebuxostat for treating chronic goutThe role of uric acid in kidney fibrosis: experimental evidences for the causal relationship.Management of hyperuricemia in gout: focus on febuxostat.Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndromeUltra-performance liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in dog plasma and its application to a pharmacokinetic study.Febuxostat in the management of hyperuricemia and chronic gout: a review.Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia.A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals.Febuxostat: drug review and update.Febuxostat-induced acute liver injury.Allopurinol for pain relief: more than just crystal clearance?Toward an Understanding of Structural Insights of Xanthine and Aldehyde Oxidases: An Overview of their Inhibitors and Role in Various Diseases.XOR inhibition with febuxostat accelerates pulmonary endothelial barrier recovery and improves survival in lipopolysaccharide-induced murine sepsis.Febuxostat improves the local and remote organ changes induced by intestinal ischemia/reperfusion in rats.Development and validation of a stability-indicating RP-HPLC method for the determination of febuxostat (a xanthine oxidase inhibitor).Febuxostat (Uloric), A New Treatment Option for Gout.New urea and thiourea derivatives of piperazine doped with febuxostat: synthesis and evaluation of anti-TMV and antimicrobial activities.Determination of Febuxostat in Human Plasma Using RP-LC-UV Method.
P2860
Q24202984-BC56F19E-A419-4FB5-BC2E-CBFD24F8CDF4Q24236637-034D447A-C415-4F12-9825-E45713D4CBA0Q33634704-0D2A0A82-8A31-4936-8DA3-D6D3C4A6386FQ33635542-558D54EF-777F-4378-98CA-CEDA1F064806Q34141630-B76621AA-8904-49A2-A2AF-F6AF0AA5A362Q34317925-71D7ABAB-8C56-4004-AE1E-00BAC4F8F14CQ34658300-ABC65F40-6757-4CDE-9308-388B1EEFD460Q35026721-E8537F9E-94E9-428E-8CD5-80F4E261A064Q36302521-E8F0CC8D-E72E-4FCF-8C8C-D7C65AAAB443Q37434571-4A97E2AF-28BF-42E8-98C1-17637B8BA8EFQ38200657-76C23A2F-EE1C-425D-9C3C-478DCED9B785Q38603701-1BBFAEFF-EABB-4B41-AB49-3BA8336DC8F1Q39309180-0B599011-DE2A-4740-8BBC-AE9D6D2F5B30Q39411224-51A0DA16-FDBF-44EF-8264-464E41A046F4Q41386068-8FB46C74-ACF9-43FF-95DE-2057C73FB95EQ45918307-EDB997A6-1996-425F-97D7-E5C95003CAF4Q46028148-B4820360-935F-4287-B5E2-5364ADD22E61Q47122811-CFF7B63B-E1AF-4743-BB88-18D6B6A9688EQ51851918-F514B49A-CD5F-4F6E-BA8E-89F8FD7A9A55Q53766440-C63006AA-8F1C-413D-A996-746022175AF4
P2860
Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Febuxostat: a selective xanthi ...... ent of hyperuricemia and gout.
@ast
Febuxostat: a selective xanthi ...... ent of hyperuricemia and gout.
@en
Febuxostat: a selective xanthi ...... ent of hyperuricemia and gout.
@nl
type
label
Febuxostat: a selective xanthi ...... ent of hyperuricemia and gout.
@ast
Febuxostat: a selective xanthi ...... ent of hyperuricemia and gout.
@en
Febuxostat: a selective xanthi ...... ent of hyperuricemia and gout.
@nl
prefLabel
Febuxostat: a selective xanthi ...... ent of hyperuricemia and gout.
@ast
Febuxostat: a selective xanthi ...... ent of hyperuricemia and gout.
@en
Febuxostat: a selective xanthi ...... ent of hyperuricemia and gout.
@nl
P2860
P356
P1476
Febuxostat: a selective xanthi ...... ent of hyperuricemia and gout.
@en
P2093
Susan P Bruce
P2860
P304
P356
10.1345/APH.1H121
P407
P577
2006-11-28T00:00:00Z